Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

Novel uses of androgen receptor inhibitors in cancer

Repurposing of androgen receptors inhibitors for prostate cancer treatment to treat other cancer in males such as melanoma.

Problem: 

For many cancer types, women have lower incidence and better outcomes than men. The role of sex steroid hormones, such as estrogen and testosterone, has been studied in reproductive organ cancers such as prostate and breast cancer, but not in other non-androgen (AR)-driven cancers. Recent studies have shown that testosterone promotes cancer cell proliferation. 

Solution: 

Inhibiting testosterone-induced tumor growth as a new therapeutic approach for non-AR-driven cancer. 

Technology Overview: 

Dr. Ridky and colleagues demonstrated that testosterone promotes cancer cell proliferation through a non-AR-dependent mechanism.  Four existing FDA-approved androgen receptor inhibitors, flutamide, bicalutamide, enzalutamide, and apalutamide, are inhibiting the proliferation of different cancer cell lines, from non-reproductive non-AR expressing tissues. Hence these therapeutics may have a way broader therapeutic effect than earlier contemplated. 

Advantages: 

Enhance effectiveness of current cancer therapy treatment using already approved drugs 

 

Top Figure: Both bicalutamide (CDX) and enzalutamide (ENZ) completely block testosterone-induced proliferation of melanoma cell lines. Bottom Figure: Tumor growth in SCID male mice bearing WM46-derived subcutaneous tumors was inhibited by Apalutamide (20mg/kg/day via oral gavage).

Stage of Development: 

Intellectual Property: 

Patent application filed

Desired Partnerships: 

Sponsored research and licensing
Patent Information:

Inventors:

Todd Ridky
Cristina Aguirre Portol├ęs
Christopher Natale

Docket # 20-9153

For Information, Contact:

Viviane Martin
University of Pennsylvania
215-746-4275
martinv@upenn.edu

Keywords:

Oncology